新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » 癌症研究 » Cancer:胃肠道间质瘤病人或患其它癌症的风险较高

Cancer:胃肠道间质瘤病人或患其它癌症的风险较高

来源:生物谷 2015-05-04 11:43

2015年5月4日 讯 /生物谷BIOON/ --近日,来自加州大学圣地亚哥分校医学院的研究人员在杂志Cancer上刊登了其最新研究成果,他们首次进行了一项基于人口的调查,将胃肠道间质瘤(GIST)同其它癌症的发病风险相互联系了起来,研究结果表明,在5.8名GIST患者中就有1人在疾病诊断前或者诊断后患其它恶性肿瘤。

研究者表示,GIST患者更易于患其它肉瘤疾病、非霍奇金淋巴瘤、类癌瘤、黑色素瘤、结直肠癌、胰腺癌以及非小细胞肺癌等癌症;而仅有5%的GIST患者存在遗传性障碍,促使其患多发性的良性或恶性肿瘤,本文研究表明,这些GIST患者患癌或许并不局限于上述症状,但具体的机制目前尚不清楚。

后期研究者将通过更多的研究来揭示GIST和其它癌症之间的关联,诊断为GIST的病人通常会进行基于其它癌症的额外筛查,而这些其它癌症往往是患者最易感的;研究者在美国人群中研究发现,患者在GIST诊断前癌症发生的流行率会增加44%,而在GIST诊断后患其它癌症的风险会增加66%,而患者最常见的肿瘤则为泌尿生殖道、乳腺、呼吸道及血液肿瘤等。

非西班牙裔病人在GIST诊断前患其它癌症的发病率较高,肿瘤尺寸小于10厘米的患者相比肿瘤尺寸较大的患者而言患第二种癌症的可能性较大;而肿瘤尺寸小于2厘米的患者患其它恶性肿瘤的可能性是最高的,而这与GIST诊断前后无关。(生物谷Bioon.com)

本文系生物谷原创编译整理,欢迎转载!转载请注明来源并附原文链接。更多资讯请下载生物谷APP.

Increased risk of additional cancers among patients with gastrointestinal stromal tumors: A population-based study.

Murphy JD1, Ma GL, Baumgartner JM, Madlensky L, Burgoyne AM, Tang CM, Martinez ME, Sicklick JK.

BACKGROUND:Most gastrointestinal stromal tumors (GISTs) are considered nonhereditary or sporadic. However, single-institution studies suggest that GIST patients develop additional malignancies at increased frequencies. It was hypothesized that greater insight could be gained into possible associations between GISTs and other malignancies with a national cancer database inquiry. METHODS: Patients diagnosed with GISTs (2001-2011) in the Surveillance, Epidemiology, and End Results database were included. Standardized prevalence ratios (SPRs) and standardized incidence ratios (SIRs) were used to quantify cancer risks incurred by GIST patients before and after GIST diagnoses, respectively, in comparison with the general US population. RESULTS: There were 6112 GIST patients, and 1047 (17.1%) had additional cancers. There were significant increases in overall cancer rates: 44% (SPR, 1.44) before the GIST diagnosis and 66% (SIR, 1.66) after the GIST diagnosis. Malignancies with significantly increased occurrence both before and after diagnoses included other sarcomas (SPR, 5.24; SIR, 4.02), neuroendocrine-carcinoid tumors (SPR, 3.56; SIR, 4.79), non-Hodgkin lymphoma (SPR, 1.69; SIR, 1.76), and colorectal adenocarcinoma (SPR, 1.51; SIR, 2.16). Esophageal adenocarcinoma (SPR, 12.0), bladder adenocarcinoma (SPR, 7.51), melanoma (SPR, 1.46), and prostate adenocarcinoma (SPR, 1.20) were significantly more common only before the GIST diagnosis. Ovarian carcinoma (SIR, 8.72), small intestine adenocarcinoma (SIR, 5.89), papillary thyroid cancer (SIR, 5.16), renal cell carcinoma (SIR, 4.46), hepatobiliary adenocarcinoma (SIR, 3.10), gastric adenocarcinoma (SIR, 2.70), pancreatic adenocarcinoma (SIR, 2.03), uterine adenocarcinoma (SIR, 1.96), non-small cell lung cancer (SIR, 1.74), and transitional cell carcinoma of the bladder (SIR, 1.65) were significantly more common only after the GIST diagnosis. CONCLUSIONS: This is the first population-based study to characterize the associations and temporal relations between GISTs and other cancers by both site and histological type. These associations may carry important clinical implications for future cancer screening and treatment strategies. Cancer 2015. © 2015 American Cancer Society.

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库